15 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
Gates Foundation, and will be conducted by the HIV Vaccine Trials Network. NIAID has provided funding throughout the product development lifecycle of VIR
8-K
EX-99.1
VIR
Vir Biotechnology Inc
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm
of the National Institutes of Health, through grant funding to HVTN. NIAID has provided funding throughout the product development lifecycle of VIR-1388
8-K
EX-99.1
39mkjjh
19 Jun 20
Patent License Agreement
5:26pm
10-K
w2xlcg
26 Mar 20
Annual report
4:08pm
424B4
izrks43x40520e96
11 Oct 19
Prospectus supplement with pricing info
5:31pm
S-1/A
gxtbypo 2zf3r7o2sef
30 Sep 19
IPO registration (amended)
6:12am
S-1
EX-10.44
wre2hld8a 68uw37y
3 Sep 19
IPO registration
4:40pm
S-1
saar xg9zb3dimy7d
3 Sep 19
IPO registration
4:40pm
DRS/A
0usucp6d
7 Aug 19
Draft registration statement (amended)
12:00am
DRS
afe34j8v5tob38u299
27 Jun 19
Draft registration statement
12:00am
- Prev
- 1
- Next